They have based their estimate on the figures for prevalence and incident in the period between 2000 and 2004 which show a steady rise in the national incidence of diagnosed diabetes.

This projection represents 9.3 million more people with diagnosed diabetes than previously thought.

The fastest growing ethnic group with diagnosed diabetes is expected to be Hispanic and the fastest growing age group the 75 year olds.

According to the International Diabetes Federation over the last 20 years the total number of people with diabetes worldwide has risen from 30 million to 230 million, with China and India the top of the league table when it comes to who has the most diabetes sufferers in the world.

Seven of the top ten countries with diabetes are developing countries and in the Caribbean and the Middle East the percentage of adults with diabetes in some areas has reached 20%.

In other developing countries diabetes can mean death within one or two years.

There is little doubt that spread of type 2 diabetes can be attributed to lifestyle, diet and genetics and the combination of bad diet and inactivity leads to weight gain, which in turn raises the risk of developing diabetes type 2.

Researchers say there are 6 million new diabetes sufferers in the world each year and it is now the fourth largest cause of death worldwide.

Many sufferers are unaware they have the disease which causes blindness, cardiovascular disease and often means the amputation of affected limbs.

The researchers say that the primary prevention of diabetes is an urgent priority or the future burden of diabetes will be even more alarming than previously thought.

The research was presented the American Diabetes Association's 66th Scientific Session.

Once again, using cell cultures, Omekawa et al exposed confluent cultures of NRK52E cells to calcium oxalate monohydrate (COM) with or without pretreatment with diphenileneiodium chloride (DPI). They hypothesized that this latter agent would attenuate increased MCP1 (Monocyte chemotactic protein-1) production induced by COM. They also evaluated production of reactive oxygen species (ROS). Within this alphabet soup of abbreviations, they believe they showed that generation of low concentration of ROS, possibly by NADPH oxidase, may represent a second messenger system for generation of COM induced MCP1 in the renal tubules. #1044

Moving to animal models, Straub and his colleagues used micropuncture techniques in the rat model to investigate The Role of Angiotensin 2 Receptor Subtypes in the Regulation of the Oxalate Transport in the Nephron. They had already demonstrated that angiotensin 2 inhibited oxalate transport, resulting in higher urinary oxalate excretion. In this present experiment, they pretreated with AT1-receptor blocker Losartan?® or the AT2 blocker PD123319. They measured luminal oxalate by micropuncture. Losartan?® decreased transport but PD123319 increased transport. Hence, both receptor subtypes are involved in mediation of Angiotensin 2 renal oxalate transport. This knowledge may assist in future search for an oxalate blocker. One questioner expressed concern that treatment to decrease oxalate transport to urine would result in a deleterious increase in serum oxalate. Straub responded that perhaps this would be the result. #1045

S. Marengo and her associates again used a rat model to study Continuous Infusion of Oxalate (Ox) Increases Intrarenal Concentrations of Calcium at Doses and in Regions Not Associated with Calcium Oxalate Nephrocalcinosis. They used a mini-pump to infuse excessive potassium oxalate subcutaneously for 2 weeks. There was a complex relationship between doses of oxalate and resulting levels of nephrocalcinosis: 100% at 360 mM infusion per day, but only 28% at 300 mM/d and rarely at 240 mM/d. In addition, a second experiment showed increased amounts of intra-renal calcium in addition to increased amounts of oxalate.  They propose that oxalate driven increases in calcium could play a role in the development of calcium oxalate nephrocalcinosis. #1046

In the last paper of the session, Wen and his co-workers wished to determine if action of ketorolac resulted from inhibition of contractility or nociception. They used a pig ureter strip model to measure effects of various concentrations of ketorolac and compared its effect(s) to positive control indomethacin, and negative control DMSO. Ketorolac decreased ureteral contractility in a dose dependent fashion and was similar to indomethacin. DMSO resulted in minimal decreases in contractility. They suggest that local application of ketorolac might result in decreased stent pain, decreased edema and increased stone passage. #1047

UroToday - the only urology website with original content global urology key opinion leaders actively engaged in clinical practice.